Key facts
- It has raised $74.1M; the latest was Debt - General ($2.0M) in Dec 2024.
- Notable investors include Eclipse Ventures, Mayo Clinic, Echo Investment Capital, Granger Management, AstraZeneca — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Nucleus RadioPharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Nucleus RadioPharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nucleus RadioPharma
Operato of an end-to-end contract development and manufacturing organization intended to build robust and reliable clinical and commercial supply chains. The company offers commercial-scale facilities in proximity to prominent destination medical centers and key distribution hubs, enabling innovators to avail help at any point in their product lifecycle and receive optimal services to rapidly advance their program.
- Sector
- Healthcare
- HQ
- Davidson, NC, United States
- Founded
- 2022
- Employees
- 43
- Website
- nucleusrad.com/
- Ownership
- Privately Held (backing)
Nucleus RadioPharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nucleus RadioPharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nucleus RadioPharma in its N-PORT filings yet. We sweep new filings monthly.